Investment Q&A

Q: In any otherwise well diversified RIF portfolio I am considering exiting T and BEP.

I am looking to replace them with a couple of holdings that you feel have far greater upside in the next 3-5 years (realizing that the volatility may increase to some extent but in line with the potential for greater returns).

I have referred to several of your current favourites (which we do not currently hold) as potentials and am open to other suggestions you might have along the same lines.

If you could comment on the elimination of T and BEP and also if you believe any of the listed ones (or others ) would provide a substantially better risk/rewad profile over the next 3-5 years it would be appreciated.

Thanks,

Terry

Q: I acknowledge that timing a revenue growth inflection is a fraught undertaking. Could you suggest one or two stocks that you believe have the best opportunity and your thinking.

Q: I need to trim SMCI, NVDA and VRT. I have partial positions in AMZN, MSFT, AMD, LLY,GOOG, AXON, NXT, CELH, PLTR and NTNX. Could you please order the partial positions from high to low, for a potential add? What are your recommendations for 4 or 5 other growth stocks, any size/sector that I could investigate for a new position? Would any of the these growth stocks fit into the ranking of the partial positions? If so, could you place them into the ranking? Thanks very much for this service and the patience you show, in answering the many questions!

Q: Further to Peter's column in the Financial Post [always good, plain ,common sense advice] I'm wondering what US companies in the health care sector might be considered?
Thanks

Q: Can i get you opinion on TMDX after their latest results? As well, could you please give me your favorite healthcare stocks? And rank them for order of purchase today. Thanks

Q: Small caps have lagged the market. What are your top 5 Small Cap Canadian Names and top 5 US Small Cap names? Could you also indicate good entry points. Please deduct appropriate credits.

Thanks
Tim

Q: TMDX is in the business of delivering viable human organs for transplant operations. Their technology markedly improves organ viability compared to the previous methodology of placing organs on ice. Future competitors must demonstrate via clinical trials that their technology is significantly better than that of TMDX. Seems like a decent moat. TMDX took on further debt to by a small airline to facilitate organ delivery which was being hampered by lack of reliable air transport. I would appreciate your expertise in determining if TMDX has a valid business model that warrants investment in their stock at its current price.